Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alberto Leoni is active.

Publication


Featured researches published by Alberto Leoni.


Journal of Medicinal Chemistry | 2008

New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues.

Aldo Andreani; Silvia Burnelli; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Natalia Calonghi; Concettina Cappadone; Giovanna Farruggia; Maddalena Zini; Claudio Stefanelli; Lanfranco Masotti; Norman S. Radin; Robert H. Shoemaker

The synthesis of new antitumor 6-substituted imidazothiazole guanylhydrazones is described. Moreover, a series of compounds with a different basic chain at the 5 position were prepared. Finally, the replacement of the thiazole ring in the imidazothiazole system was also considered. All the new compounds prepared were submitted to the NCI cell line screen for evaluation of their antitumor activity. A few selected compounds were submitted to additional biological studies concerning effects on the cell cycle, apoptosis, and mitochondria.


European Journal of Medicinal Chemistry | 2001

Synthesis and antitubercular activity of imidazo[2,1-b]thiazoles

Aldo Andreani; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi

A number of selected imidazo[2,1-b]thiazoles entered the screening at the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) and one of these compounds, 2-chloro-6-phenylimidazo[2,1-b]thiazole, showed antitubercular activity. On this basis we planned the synthesis of new analogues bearing a substituted ring at the 6 position. For one compound only (2-chloro-6-p-chlorophenylimidazo[2,1-b]thiazole) the 5-nitroso derivative was also prepared. The antitubercular activity of these compounds was compared with the known analogues lacking the chlorine at the 2 position. 5-Nitroso-6-p-chlorophenylimidazo[2,1-b]thiazole showed potent antitubercular activity.


Journal of Medicinal Chemistry | 2008

Antitumor Activity of Bis-Indole Derivatives

Aldo Andreani; Silvia Burnelli; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Laura Landi; Cecilia Prata; Michael V. Berridge; Carole Grasso; Heinz-Herbert Fiebig; Gerhard Kelter; Angelika M. Burger; Mark W. Kunkel

This paper reports the synthesis of compounds formed by two indole systems separated by a heterocycle (pyridine or piperazine). As a primary screening, the new compounds were submitted to the National Cancer Institute for evaluation of antitumor activity in the human cell line screen. The pyridine derivatives were far more active than the piperazine derivatives. For the study of the mechanism of action, the most active compounds were subjected to COMPARE analysis and to further biological tests including proteasome inhibition and inhibition of plasma membrane electron transport. The compound bearing the 5-methoxy-2-indolinone moiety was subjected to the first in vivo experiment (hollow fiber assay) and was active. It was therefore selected for the second in vivo experiment (human tumor xenograft in mice). In conclusion we demonstrated that this approach was successful, since some of the compounds described are much more active than the numerous, so far prepared and tested 3-indolylmethylene-2-indolinones.


Journal of Medicinal Chemistry | 2008

Antitumor Activity of New Substituted 3-(5-Imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-Imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones : Selectivity against Colon Tumor Cells and Effect on Cell Cycle-Related Events

Aldo Andreani; Silvia Burnelli; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Natalia Calonghi; Concettina Cappadone; Manuela Voltattorni; Maddalena Zini; Claudio Stefanelli; Lanfranco Masotti; Robert H. Shoemaker

The synthesis of new 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones is reported. The antitumor activity was evaluated according to the protocols available at the National Cancer Institute (NCI), Bethesda, MD. To investigate the mechanism of action of the most potent antitumor agent of this series, its effect on growth of HT-29 colon carcinoma cells was studied. Its ability to inhibit cellular proliferation was mediated by cell cycle arrest at the G2/M phase, accompanied by inhibition of ornithine decarboxylase (ODC), the limiting enzyme of polyamine synthesis, and followed by induction of apoptosis.


Bioorganic & Medicinal Chemistry | 2000

Potential antitumor agents. part 291: synthesis and potential coanthracyclinic activity of Imidazo[2,1-b]thiazole guanylhydrazones

Aldo Andreani; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Maurizio Recanatini; Vida Garaliene

This paper reports the synthesis of new imidazo[2,1-b]thiazole guanylhydrazones which were tested as potential antitumor agents. Three of these derivatives (those bearing a 3- or 4-nitrophenyl group) were the most potent and one of these showed a mild effect as CDK1 inhibitor. These same three derivatives were also tested as positive inotropic agents and two of them were more potent than amrinone at 10(-5) M. These two guanylhydrazones could be useful coanthracyclinic agents.


European Journal of Medicinal Chemistry | 2011

Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.

Aldo Andreani; Massimiliano Granaiola; Alberto Leoni; Alessandra Locatelli; Rita Morigi; Mirella Rambaldi; Lucilla Varoli; Deborah A. Lannigan; Jeffrey S. Smith; Dominic A. Scudiero; Robert H. Shoemaker

The activity of a series of imidazo[2,1-b]thiazole guanylhydrazones as inhibitors of p90 ribosomal S6 kinase 2 (RSK2) is described. It was found that a small subset of compounds show both potent inhibition of RSK2 kinase activity and tumor cell growth in vitro. Detailed study of one of the most active compounds indicates a high degree of selectivity for inhibition of RSK2 compared to a spectrum of other related kinases. Selective inhibition of the MCF-7 breast tumor cell line compared to MCF-10A non-transformed cells, as well as selective inhibition of the biomarker GSK3 provides evidence that the compounds can affect the RSK2 target in cells.


European Journal of Medicinal Chemistry | 1996

Synthesis and cardiotonic activity of imidazo[2,l-b]thiazoles bearing a lactam ring

Aldo Andreani; Mirella Rambaldi; Alberto Leoni; Alessandra Locatelli; Rosaria Bossa; M Chiericozzi; I. Galatulas; Gaetano Salvatore

Summary This paper describes the synthesis of 6-substituted imidazo[2,1- b ]thiazoles with a lactam ring connected, by means of a methine group, to the 5-position. The pharmacological results show that interesting cardiotonic activity is obtained when the lactam ring is pseudothiohydantoin ( 8 ) or barbituric acid ( 9 ). Even the substituent at position 6 plays an important role in the pharmacological behavior of these derivatives. The following activity rank order was observed: phenyl > methyl > chlorine.


Journal of Pharmaceutical and Biomedical Analysis | 1999

Photodegradation studies on Atenolol by liquid chromatography

Vincenza Andrisano; Roberto Gotti; Alberto Leoni; Vanni Cavrini

The photostability of the beta-blocker drug Atenolol was evaluated at pH 9, 7.4 and 4.0. The drug was exposed to UVA-UVB radiations and the photoproducts were detected by reversed phase LC methods. The photodegradation was found to increase with the pH value decreasing. The major photodegradation product at pH 7.4 was identified as 2-(4-hydroxyphenyl)acetamide. The LC method developed for routine analyses (column: C-18 Alltima; mobile phase: TEA acetate (pH 4; 0.01 M)-acetonitrile 96:4) was found to be suitable for the stability indicating determination of Atenolol in pharmaceutical dosage forms.


European Journal of Medicinal Chemistry | 1997

Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones†

Aldo Andreani; Alessandra Locatelli; Alberto Leoni; Mirella Rambaldi; Rita Morigi; Rosaria Bossa; M Chiericozzi; Alessandra Fraccari; I. Galatulas

Summary A compound endowed with coanthracyclinic activity should potentiate the antitumor activity of anthracyclines while counteracting their cardiodepressant effect. We now report the synthesis and configuration of a series of substituted 3-(5-imidazo[2,1- b ]thiazolylmethylene)-2-indolinones which were tested for both cardiotonic and cytotoxic activity. Several compounds were potent cytotoxic agents and two of them (in particular 3-[6-(2,5-dimethoxyphenyl)-5-imidazo[2,1- b ]thiazolylmethylene]-2 -indolinone, which showed even cardiotonic activity, are potential coanthracyclinic agents.


Journal of Medicinal Chemistry | 2011

Cystic Fibrosis: A New Target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines

Roberta Budriesi; Pierfranco Ioan; Alberto Leoni; Nicoletta Pedemonte; Alessandra Locatelli; Matteo Micucci; Alberto Chiarini; Luis J. V. Galietta

The pharmacology of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl– channel has attracted significant interest in recent years with the aim to search for rational new therapies for diseases caused by CFTR malfunction. Mutations that abolish the function of CFTR cause the life-threatening genetic disease cystic fibrosis (CF). The most common cause of CF is the deletion of phenylalanine 508 (ΔF508) in the CFTR chloride channel. Felodipine, nifedipine, and other antihypertensive 1,4-dihydropyridines (1,4-DHPs) that block L-type Ca2+ channels are also effective potentiators of CFTR gating, able to correct the defective activity of ΔF508 and other CFTR mutants (Mol. Pharmacol.2005, 54, 1736). For this purpose, we evaluated the ability of the previously and newly synthesized 4-imidazo[2,1-b]thiazoles-1,4-dihydropyridines without vascular activity and inotropic and/or chronotropic cardiac effects (J. Med. Chem.2008, 54, 1592) to enhance the activity of ΔF508-CFTR. Our studies indicate compounds 17, 18, 20, 21, 38, and 39 as 1,4-DHPs with an interesting profile of activity.

Collaboration


Dive into the Alberto Leoni's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge